Evidence map›Paper›PMID 39557490›Full record

ArticleRMD open2024

Gut microbiota in very early systemic sclerosis: the first case-control taxonomic and functional characterisation highlighting an altered butyric acid profile.

Silvia Bellando-Randone, Edda Russo, Leandro Di Gloria, Gemma Lepri, Simone Baldi, Bianca Saveria Fioretto, Eloisa Romano, Giulio Ghezzi, Sara Bertorello, Khadija El Aoufy and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RMD open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Silvia Bellando-Randone *Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Florence, Italy.ORCID 0000-0002-5926-6263
Edda Russo *Department of Experimental and Clinical Medicine, Section of Internal Medicine, University of Florence, Florence, Italy.ORCID 0000-0003-3141-1091
Leandro Di GloriaDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.
Gemma LepriDepartment of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Florence, Italy.
Simone BaldiDepartment of Experimental and Clinical Medicine, Section of Internal Medicine, University of Florence, Florence, Italy.
Bianca Saveria FiorettoDepartment of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence, Florence, Italy.
Eloisa RomanoDepartment of Experimental and Clinical Medicine, Section of Internal Medicine, University of Florence, Florence, Italy.
Giulio GhezziDepartment of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Florence, Italy.
Sara BertorelloDepartment of Experimental and Clinical Medicine, Section of Internal Medicine, University of Florence, Florence, Italy.
Khadija El AoufyDepartment of Health Sciences, University of Florence, Florence, Italy.
Irene RosaDepartment of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence, Florence, Italy.
Marco PallecchiDepartment of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Cosimo BruniDepartment of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Florence, Italy.ORCID 0000-0003-2813-2083
Francesco CeiDepartment of Experimental and Clinical Medicine, Section of Internal Medicine, University of Florence, Florence, Italy.
Giulia NanniniDepartment of Experimental and Clinical Medicine, Section of Internal Medicine, University of Florence, Florence, Italy.
Elena NiccolaiDepartment of Experimental and Clinical Medicine, Section of Internal Medicine, University of Florence, Florence, Italy.ORCID 0000-0002-9205-8079
Martina OrlandiDepartment of Medical and Surgical Sciences for Children, University of Modena and Reggio Emilia, Modena, Italy.
Giulia BandiniDepartment of Experimental and Clinical Medicine, Section of Internal Medicine, University of Florence, Florence, Italy.
Serena GuiducciDepartment of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Florence, Italy.
Gian Luca BartolucciDepartment of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Florence, Italy.
Matteo RamazzottiDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.
Mirko ManettiDepartment of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence, Florence, Italy.ORCID 0000-0003-3956-8480
Marco Matucci-CerinicUnit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy MatucciCerinic.Marco@hsr.it.ORCID 0000-0002-9324-3161
Amedeo AmedeiDepartment of Experimental and Clinical Medicine, Section of Internal Medicine, University of Florence, Florence, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesIn systemic sclerosis (SSc), gastrointestinal involvement is one of the earliest events. We compared the gut microbiota (GM), its short-chain fatty acids (SCFAs) and host-derived free fatty acids (FFAs) in patients with very early diagnosis of SSc (VEDOSS) and definite SSc.

methodsStool samples of 26 patients with SSc, 18 patients with VEDOSS and 20 healthy controls (HC) were collected. The GM was assessed through 16S rRNA sequencing, while SCFAs and FFAs were assessed by gas chromatography-mass spectrometry.

resultsIn patients with VEDOSS, an increase in Bacteroidales and Oscillospirales orders and a decrease in Bacilli class,

conclusionA GM dysbiosis with depletion of beneficial anti-inflammatory bacteria (especially butyrate-producing) and a significant decrease in faecal butyrate was identified in patients with VEDOSS. This early GM imbalance may foster the growth of inflammatory microbes, worsening intestinal dysbiosis and inflammation in early SSc stages. The potential butyrate administration in early disease phases might be considered as a novel therapeutic approach to mitigate gastrointestinal discomfort and progression preserving patient's quality of life.

Indexed as

Butyric AcidFecesGastrointestinal MicrobiomeRNA, Ribosomal, 16SScleroderma, SystemicAdultAgedBacteriaCase-Control StudiesDysbiosisFatty Acids, VolatileFemaleHumansMaleMiddle AgedButyric AcidFatty Acids, VolatileRNA, Ribosomal, 16Sinflammationlipidssystemic sclerosis

Identifiers

PMID39557490
PMCPMC11574430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.